Cantor Fitzgerald Forecasts Ultragenyx Pharmaceutical’s FY2023 Earnings

Trending News 🌥️

Cantor Fitzgerald analysts have released their forecast for Ultragenyx Pharmaceutical ($NASDAQ:RARE) Inc.’s FY2023 earnings per share. Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics to treat rare and ultra-rare genetic diseases. Through a pipeline of novel therapies, Ultragenyx Pharmaceutical is working to improve the lives of patients with serious genetic diseases. Its therapies are designed to treat a variety of diseases, including rheumatologic and metabolic disorders, cardiovascular conditions, and oncology.

In addition, Ultragenyx Pharmaceutical is investing in gene therapy research and development to develop potential treatments for a range of genetic diseases. As the company continues to build its pipeline of therapies, analysts believe that it could achieve greater success in FY2023 and beyond.

Earnings

According to the firm’s earning report from the fourth quarter of FY2022, ending December 31 2022, Ultragenyx Pharmaceutical Inc. earned a total revenue of 103.35M USD and lost 151.83M USD in net income. This is an increase of 23.9% compared to the previous year, and a total revenue growth of 103.35M USD over the last three years. Analysts from Cantor Fitzgerald remain hopeful that these figures will continue to rise in the future, showing an upward trend in the company’s profits and earnings.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Ultragenyx Pharmaceutical. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Ultragenyx Pharmaceutical. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Ultragenyx Pharmaceutical. More…

Key Ratios Snapshot

Some of the financial key ratios for Ultragenyx Pharmaceutical are shown below. More…

Price History

On Tuesday, ULTRAGENYX PHARMACEUTICAL stock opened at $43.7 and closed at $42.5, down by 3.5% from the previous closing price of 44.0. This decrease in stock price could be attributed to investor uncertainty surrounding the company’s financial performance next year. It is yet to be seen how accurate Cantor Fitzgerald’s prediction will prove to be; until then investors will have to wait and see how the stock performs in the coming months. Live Quote…

Analysis

At GoodWhale, we have analyzed the fundamentals of ULTRAGENYX PHARMACEUTICAL and have determined that it is a high risk investment when it comes to both financial and business aspects. We have identified 4 potential risks that investors should be aware of. These risks can be found across the income sheet, balance sheet, cashflow statement, and non-financial areas. To gain more insights, you can log onto goodwhale.com and check out our detailed analysis. We encourage all investors to do thorough research before making any decisions. More…

Peers

The competition in the pharmaceutical industry is fierce, with companies constantly vying for market share. This is especially true in the area of rare disease treatments, where there are often only a few companies competing for patients. Ultragenyx Pharmaceutical Inc is one such company, and it competes against Cassiopea SpA, Poxel SA, and Ampio Pharmaceuticals Inc, among others.

– Cassiopea SpA ($LTS:0RA2)

Poxel SA is a pharmaceutical company that focuses on the development of treatments for diabetes and obesity. The company has a market capitalization of $42.92 million and a return on equity of -705.2%. Poxel SA’s products include Imeglimin, which is in clinical development for the treatment of type 2 diabetes, and PXL065, which is in preclinical development for the treatment of obesity.

Summary

Investment analysts at Cantor Fitzgerald have released their earnings estimates for Ultragenyx Pharmaceutical Inc. for the fiscal year 2023. The stock price decreased shortly after the release of these estimates, indicating a bearish outlook for the company. Investors should look for further analysis and details about the company’s performance and outlook before making any decisions about investing in Ultragenyx. It is also important to review the company’s past performance and financials in order to gain a more complete understanding of the company’s prospects.